FDA and CMS Collaborate to Streamline Regulation of Medical AI, Averting Potential Gridlock

Health officials from the FDA and CMS are working to prevent regulatory conflicts between state and federal authorities regarding artificial intelligence used in clinical tasks, including systems that can write prescriptions. The initiative aims to avoid confusion from overlapping jurisdictions that could hinder the adoption of AI in healthcare. States typically regulate medical practice, while the FDA oversees medical devices, creating a complex regulatory landscape for AI performing clinical functions without human oversight.